PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2009Clinical Chemistry and Laboratory Medicine (CCLM)67 citationsOpen Access

Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study

CPConcetta PronteraFondazione Toscana Gabriele MonasterioMZMartina ZaninottoGeneral / Preventive / LipidsSGS GiovanniniIstituto di Fisiologia Clinica

Key Result

The mean total variability for BNP immunoassays (50.6 %CV) was significantly higher than that for NT-proBNP immunoassays (8.4 %CV), with between-method differences comprising the majority of BNP variability.

Study Design

Type

Observational (n=112)

Multicenter

Yes

Structured PICO

What are the differences in analytical performance between various commercial BNP and NT-proBNP immunoassays?

P
Population
112 Italian clinical laboratories participating in a proficiency testing program to evaluate the analytical performance of BNP and NT-proBNP immunoassays using 28 pooled plasma and serum samples.
E
Exposure
BNP and NT-proBNP immunoassays
C
Comparator
Different commercial immunoassay methods
O
Outcome
Differences in analytical performance (variability, imprecision, systematic differences)surrogate

There are significant analytical differences among commercial BNP immunoassays, highlighting the need for caution when comparing results from different laboratories or methods.

Main Result

Absolute Event Rate: 50.6% vs 8.4%

Limitations

  • Use of lyophilized plasma and serum samples may introduce non-homogeneity and non-commutability issues.
  • Differences in recovery of analyte following lyophilization between different immunoassay methods.
  • Lack of an artificial material commutable for all BNP and NT-proBNP immunoassay methods.

Abstract

BACKGROUND: We organized and conducted a proficiency testing study (CardioOrmocheck) to evaluate the differences in analytical performance of brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) immunoassays. METHODS: Approximately 90 Italian laboratories were involved in the 2005-2007 proficiency testing cycles, while 112 laboratories took part in the 2008 cycle (from January to May 2008). A total of 28 study samples were measured by participating laboratories for a total of 2354 determinations. RESULTS: The mean total variability for BNP (50.6 %CV) was significantly higher than that for NT-proBNP (8.4 %CV). In addition, the mean variability due to differences between-methods (46.4 %CV) comprised the majority of the total variability for BNP. Between-method variability for BNP comprised, on average, 84% of total variability, while the within-method variability comprised an average of 20.2 %CV. On the contrary, for NT-proBNP the within-method variability (7.3 %CV) represented the majority of total variability (average 75%), while between-method variability was smaller (4.1 %CV). Imprecision around the cut-off value showed marked differences among methods, especially for BNP immunoassay methods. In addition, BNP methods were affected by large systematic differences, for example an average 2.7-fold difference between Access and ADVIA Centaur methods, while agreement between NT-proBNP methods was better (an average 1.2-fold difference between Dimension and ECLIA on the Elecsys methods). CONCLUSIONS: This multicenter collaborative study demonstrates that there are significant differences in analytical characteristics and measured values among the most popular commercial methods for BNP and NT-proBNP. Clinicians should be very careful when comparing results obtained by laboratories that use different methods.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Prontera et al. (2009) conducted an observational in Proficiency testing for BNP and NT-proBNP immunoassays (n=112). BNP immunoassays vs. NT-proBNP immunoassays was evaluated on Mean total variability (%CV). The mean total variability for BNP immunoassays (50.6 %CV) was significantly higher than that for NT-proBNP immunoassays (8.4 %CV), with between-method differences comprising the majority of BNP variability.

synapsesocial.com/papers/6a4d93eb6c3ae3769c077c1chttps://doi.org/10.1515/cclm.2009.153
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analytical Performance of the N Terminal Pro B Type Natriuretic Peptide (NT-proBNP) Assay on the Elecsys™ 1010 and 2010 Analysers2004 · 158 citations
  2. 2A Systematic Review of the Diagnostic Accuracy of Natriuretic Peptides for Heart Failure2004 · 325 citations
  3. 3Measurement of Cardiac Natriuretic Hormones (Atrial Natriuretic Peptide, Brain Natriuretic Peptide, and Related Peptides) in Clinical Practice: The Need for a New Generation of Immunoassay Methods2000 · 164 citations
  4. 4Analytical Performance and Diagnostic Accuracy of Immunometric Assays for the Measurement of Plasma B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP2005 · 71 citations
  5. 5Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay2006 · 70 citations